Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × Diphtheria-Tetanus Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 3 Xanthomatosis, Cerebrotendinous 1 Recurrence 1 Oligodendroglioma 1 Melanoma 1 Medulloblastoma 1 Influenza, Human 1 Glioma 1 Diffuse Intrinsic Pontine Glioma 1

Interventions

Cyclophosphamide 41 fludarabine 31 Dexamethasone 27 venetoclax 24 Cytarabine 22 Rituximab 16 pembrolizumab 14 fludarabine phosphate 14 Filgrastim 12 Etoposide 12 Lenalidomide 11 Vincristine 10 Gemcitabine 10 Azacitidine 10 pomalidomide 9 Nivolumab 9 Interleukin-2 9 Granulocyte Colony-Stimulating Factor 9 Doxorubicin 9 Calcium Dobesilate 9 carfilzomib 8 Topotecan 8 Methotrexate 8 Everolimus 8 Decitabine 8 Bortezomib 8 Melphalan 7 Cisplatin 7 Vorinostat 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02193347 2023-12-01

RESIST

Duke University

Phase 1 Completed

24 enrolled 8 charts

Brain Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡